Ubiquitin, SUMO-1, and UCRP in camptothesin sensitivity and resistance

Annals of the New York Academy of Sciences

Volumn 922, Issue , 2000, Pages 306-308

  Desai, Shyamal D ^a   Yong, M A O ^b   Sun, M E I ^a   Tsai Kun, L I ^b   Jiaxi, W U ^a   Liu, Leroy F ^a   New Jersey, ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CAMPTOTHECIN; DNA TOPOISOMERASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; IRINOTECAN; PROTEASOME; PROTEIN; PROTEIN UCRP; SUMO 1 PROTEIN; UBIQUITIN; UNCLASSIFIED DRUG;

CANCER; CELL FUNCTION; CONFERENCE PAPER; CONJUGATION; DRUG SENSITIVITY; ENZYME DEGRADATION; PROTEIN INDUCTION; SEQUENCE HOMOLOGY;

EID: 0034515797     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2000.tb07050.x     Document Type: Conference Paper

References (7)

1. Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin
2. SUMO-1 conjugation to DNA topoisomerase I: Possible repair response to topoisomerase-mediated DNA damage
3. The interferon-inducible 15-kDa ubiquitin homolog conjugates to intracellular proteins
4. Elevation of interferon beta-inducible proteins in ataxia telangiectasia cells
5. SUMO/sentrin: Protein modifiers regulating important cellular functions
6. Herpes virus induced proteasome-dependent degradation of the nuclear bodies-associated PML and Sp 100 proteins
7. Interferon potentiates antiproliferative activity of CPT-11 against human colon cancer xenografts